Journal article
Formulation development of a live attenuated human rotavirus (RV3-BB) vaccine candidate for use in low- and middle-income countries
P Kumar, RS Shukla, A Patel, SR Pullagurla, C Bird, O Ogun, OS Kumru, A Hamidi, F Hoeksema, C Yallop, JE Bines, SB Joshi, DB Volkin
Human Vaccines and Immunotherapeutics | TAYLOR & FRANCIS INC | Published : 2021
Abstract
Formulation development was performed with the live, attenuated, human neonatal rotavirus vaccine candidate (RV3-BB) with three main objectives to facilitate use in low- and middle- income countries including (1) a liquid, 2–8°C stable vaccine, (2) no necessity for pre-neutralization of gastric acid prior to oral administration of a small-volume dose, and (3) a low-cost vaccine dosage form. Implementation of a high-throughput RT-qPCR viral infectivity assay for RV3-BB, which correlated well with traditional FFA assays in terms of monitoring RV3-BB stability profiles, enabled more rapid and comprehensive formulation development studies. A wide variety of different classes and types of pharmac..
View full abstractGrants
Awarded by State Government of Victoria
Funding Acknowledgements
The work was funded by Bill and Melinda Gates Foundation [grant #OPP1148427 awarded to Batavia Biosciences, Leiden]. The grant received by Batavia Biosciences aimed at accelerating the development of low-cost, liquid RV3-BB rotavirus vaccine for GAVI countries through formulation development and bulk process optimization for large scale manufacturing. MCRI acknowledges funding from the Bill and Melinda Gates Foundation [OPP1111055 and OPP11183101], the Australian National Health and Medical Research Council [APP491238, APP1012425, APP546496] and the Victorian Government Infrastructure Grant.